Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
- 1 May 2005
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes Care
- Vol. 28 (5), 1068-1076
- https://doi.org/10.2337/diacare.28.5.1068
Abstract
OBJECTIVE—This randomized, double-masked, placebo-controlled clinical trial tested whether oral insulin administration could delay or prevent type 1 diabetes in nondiabetic relatives at risk for diabetes. RESEARCH DESIGN AND METHODS—We screened 103,391 first- and second-degree relatives of patients with type 1 diabetes and analyzed 97,273 samples for islet cell antibodies. A total of 3,483 were antibody positive; 2,523 underwent genetic, immunological, and metabolic staging to quantify risk of developing diabetes; 388 had a 5-year risk projection of 26–50%; and 372 (median age 10.25 years) were randomly assigned to oral insulin (7.5 mg/day) or placebo. Oral glucose tolerance tests were performed every 6 months. The median follow-up was 4.3 years, and the primary end point was diagnosis of diabetes. RESULTS—Diabetes was diagnosed in 44 oral insulin and 53 placebo subjects. Annualized rate of diabetes was similar in both groups: 6.4% with oral insulin and 8.2% with placebo (hazard ratio 0.764, P = 0.189). In a hypothesis-generating analysis of a subgroup with insulin autoantibody (IAA) levels confirmed (on two occasions) ≥80 nU/ml (n = 263), there was the suggestion of benefit: annualized diabetes rate 6.2% with oral insulin and 10.4% with placebo (0.566, P = 0.015). CONCLUSIONS—It is possible to identify individuals at high risk for type 1 diabetes and to enroll them in a large, multisite, randomized, controlled clinical trial. However, oral insulin did not delay or prevent type 1 diabetes. Further studies are needed to explore the potential role of oral insulin in delaying diabetes in relatives similar to those in the subgroup with higher IAA levels.Keywords
This publication has 26 references indexed in Scilit:
- Islet Cell Antibody-Positive Relatives with Human Leukocyte Antigen DQA10102, DQB10602: Identification by the Diabetes Prevention Trial-Type 1Journal of Clinical Endocrinology & Metabolism, 2000
- Oral Administration of the Immunodominant B-chain of Insulin Reduces Diabetes in a Co-transfer Model of Diabetes in the NOD Mouse and is Associated with a Switch from Th1 to Th2 CytokinesJournal of Autoimmunity, 1997
- ORAL TOLERANCE FOR THE TREATMENT OF AUTOIMMUNE DISEASESAnnual Review of Medicine, 1997
- Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice.JCI Insight, 1996
- Oral Insulin Does Not Prevent Insulin‐dependent Diabetes Melltus in BB RatsAnnals of the New York Academy of Sciences, 1996
- History of Oral Tolerance and Mucosal ImmunityaAnnals of the New York Academy of Sciences, 1996
- Oral Administration of Human Insulin to NOD Mice Generates CD4+ T Cells that Suppress Adoptive Transfer of DiabetesJournal of Autoimmunity, 1994
- Antigen-specific immunotherapy: Oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetesDiabetes/Metabolism Research and Reviews, 1993
- Risk of diabetes in siblings and other relatives of IDDM subjectsDiabetes, 1991
- The Pittsburgh study of insulin-dependent diabetes mellitus. Risk for diabetes among relatives of IDDMDiabetes, 1982